7 Red Days In A Row: BridgeBio Pharma Stock Is Down 12%
A multi-day slide in the biotech’s stock draws attention to a business seeing rapid growth but also significant operating losses.
BridgeBio Pharma (BBIO) has seen about $1.9 billion erased from its market value as the stock moved lower for 7 consecutive trading days. The cumulative loss over this streak is 12.4%, leaving the company’s market value at about $13 billion.
For anyone holding the stock, the persistent selling has been a drag on recent returns. BridgeBio Pharma stock trades at about $66.61 a share as of 9/18/2026.
The Streak Next To The S&P 500
Here is how BBIO stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | -1.0% | 0.2% |
| 7D (Current Streak) | -12.4% | 0.2% |
| 1M (21D) | -20.7% | -0.7% |
| 3M (63D) | 0.5% | 2.0% |
| YTD 2026 | -12.9% | 11.8% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
What Do The Fundamentals Show?
The decline is specific to the company, as the S&P 500 returned +0.2% over the same 7 trading days. The company’s fundamentals present a mixed picture of high growth and deep unprofitability. Revenue over the last twelve months grew 202.4%, far outpacing the 8.1% median for S&P 500 Health Care stocks.
At the same time, the company’s operating margin over the last twelve months is -67.0%, compared to a 17.6% median across the S&P 500 Health Care sector. BridgeBio Pharma also has negative trailing earnings, which means it does not have a meaningful price-to-earnings multiple.
A Streak Is Information, Not An Instruction.
A streak of this length is notable. It tells you that a stock is caught in downward momentum and has the market’s attention, but it does not tell you what to do next. A string of losses is not, by itself, a reason to sell, just as a string of gains is not a reason to buy.
The disciplined move is to treat the streak as a prompt to check if the price still makes sense for the business. The numbers here provide a starting point for that work, weighing the company’s growth against its current lack of profitability.
If the drop has you weighing an entry, resist buying on price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still hold up.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the whole group, not the single stock. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.